1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Amgen Planning Pivotal Obesity Program For MariTide

MariTide Phase III Trials To Include Diabetes

 
• By Mandy Jackson

Executives said during Amgen’s Q1 call that the company is “encouraged” by interim Phase II data for MariTide (AMG 133) in obesity, so it is designing Phase III trials and building manufacturing capacity. 

Professional nutritionist sitting at desk and writing a meal plan, measuring tape and apple
Phase III trials are planned in obesity, related conditions and diabetes • Source: Shutterstock

Amgen, Inc. revealed during its first quarter 2024 earnings call on 2 May that it will focus its research and development investment in obesity going forward largely on MariTide (maridebart cafraglutide, AMG 133) after a look at interim Phase II results for the GIP receptor antagonist/GLP-1 agonist and the completion of a Phase I trial for the obesity candidate AMG 786. Planning is under way for a multi-indication Phase III MariTide program, but development of AMG 786 is discontinued.

Key Takeaways

  • Amgen discontinued Phase I obesity candidate AMG 786, but said after an interim look at Phase II data for MariTide (AMG 133) it is planning a Phase III program for that drug.

  • The Phase III trials will include studies in obesity, obesity-related conditions and type 2 diabetes. The company will initiate a Phase II study in diabetes later this year

“Across the portfolio, we are presently prioritizing differentiated medicines – those that stand to provide the greatest benefit for patients,” Amgen executive vice president-R&D James Bradner told the call. “Given the profile we've seen with AMG 786, we will not pursue further development

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.